The EULEV cohort study: Rates of and factors associated with continuation of levetiracetam after 1 year

British Journal of Clinical Pharmacology

Volumn 71, Issue 1, 2011, Pages 121-127

  Droz Perroteau, Cécile ^a,b,c   Dureau Pournin, Caroline ^a,b   Vespignani, Hervé ^d   Marchal, Cécile ^b   Blin, Patrick ^a,b   Blazejewski, Sylvie ^b,c   Pollet, Clothilde ^a,b   Jové, Jérémy ^b   Robinson, Philip ^b   Moore, Nicholas ^a,b,c   Fourrier Réglat, Annie ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c INSERM U657   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Antiepileptic drug; Cohort; Effectiveness; Epilepsy; Levetiracetam

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM;

ADULT; ARTICLE; BEHAVIOR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; DISEASE CONTROL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FEMALE; FRANCE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PANCYTOPENIA; PRIORITY JOURNAL; SKIN MANIFESTATION; SOMNOLENCE;

EID: 78649999980     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03805.x     Document Type: Article

References (34)

1. Shorvon SD, Van Rijckevorsel K. A new antiepileptic drug. J Neurol Neurosurg Psychiatry 2002; 72: 426-9.
2. EMEA. EMEA Keppra® Procedural steps taken and scientific information after the authorisation. 2009.
3. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41: 1276-83.
4. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42.
5. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 1179-86.
6. Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther 2009; 87: 351-5.
7. Bird JM, Joseph ZA. Levetiracetam in clinical use - a prospective observational study. Seizure 2003; 12: 613-6.
8. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, De Krom M, Aldenkamp AP. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 2007; 10: 296-303.
9. Depondt C, Yuen AW, Bell GS, Mitchell T, Koepp MJ, Duncan JS, Sander JW. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 2006; 77: 101-3.
10. Kuba R, Novotna I, Brazdil M, Kocvarova J, Tyrlikova I, Mastik J, Rektor I. Long-term levetiracetam treatment of epilepsy patients: clinical audit. Epilepsy Res 2006; 72: 111-9.
11. Nicolson A, Lewis SA, Smith DF. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 2004; 63: 568-70.
12. Brodtkorb E, Klees TM, Nakken KO, Lossius R, Johannessen SI. Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav 2004; 5: 231-5.
13. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007; 16: 296-304.
14. Peltola J, Peltola M, Auvinen A, Raitanen J, Fallah M, Keranen T. Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. Acta Neurol Scand Suppl 2009; 119: 55-60.
15. Simister RJ, Sander JW, Koepp MJ. Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy Behav 2007; 10: 336-9.
16. Mohanraj R, Parker PG, Stephen LJ, Brodie MJ. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure 2005; 14: 23-7.
17. Sander JW. New antiepileptic drugs in practice - how do they perform in the real world? Acta Neurol Scand Suppl 2005; 181: 26-9.
18. Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, Hekster YA. Diffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice. Eur J Clin Pharmacol 2004; 60: 751-8.
19. Inman W, Pearce G. Prescriber profile and post-marketing surveillance. Lancet 1993; 342: 658-61.
20. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-8.
21. Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-4.
22. Villanueva V, Gomez-Caigoya A, Gutierrez-Delicado E, Serratosa JM. [Open-label, prospective and observational study of efficacy and tolerability with levetiracetam during one year of follow-up]. Neurologia 2007; 22: 348-53.
23. Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, Hekster YA. Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands. J Clin Pharm Ther 2004; 29: 131-8.
24. Fourrier-Reglat A, Droz-Perroteau C, Benichou J, Depont F, Amouretti M, Begaud B, Moride Y, Blin P, Moore N. Impact of prescriber nonresponse on patient representativeness. Epidemiology 2008; 19: 186-90.
25. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 2007; 13: 57-78.
26. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev 2007; 13: 43-56.
27. Le Dictionnaire VIDAL, 80th edn. Paris: VIDAL, 2004.
28. Le Dictionnaire VIDAL, 81st edn. Paris: VIDAL, 2005.
29. Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure 2008; 17: 160-5.
30. Anger GJ, Piquette-Miller M. Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther 2008; 83: 184-7.
31. Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia 2006; 47: (Suppl. 1): 46-53.
32. Sohn YH, Kaelin-Lang A, Jung HY, Hallett M. Effect of levetiracetam on human corticospinal excitability. Neurology 2001; 57: 858-63.
33. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70: 54-65.
34. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007; 75: 192-6.